Full text Pdf 

http://doi.org/10.31288/oftalmolzh201113640

THE RESULTS OF LIPOFLAVON USAGE IN PATIENTS OF AGE-RELATED MACULOPATHY

Umanskaya U. V., Putienko A. A.

Odessa, Ukraine

There were analyzed the results of the lipoflavon application against the background of the basic therapy in 51 patients (102 eyes) with age-related maculopathy (AMP). The first control group consisted of 24 patients (48 eyes) who received vitamin E against the background of the basic therapy. The second control group consisted of 29 patients (57 eyes) with the basic therapy only. It was shown that lipoflavon in the patients with AMP could significantly improve the functional indices of the retina in the macular area, which was evidence of significant improvement of the threshold for the phenomenon of Haidinger, significant improvement of light sensitivity as well as significant improvements in several indicators of multifocal electroretinogram, accompanied by a statistically significant improvement in the visual acuity in the group under study compared with the controls. This allows us to recommend the drug lipoflavon for inclusion in the complex of drugs for the treatment of age-related macular degeneration.

 

References

1.Драгомирецкая Е. И. Изменение остроты зрения в октавах — важнейший клинический отклик в доказательной офтальмологии / Е. И. Драгомирецкая, О. Н. Крючкова, Т. В. Романова // Офтальмол. журн. — 2005. — № 5. — С.81-83.

2.Дудниченко А. С. Липосомальные лекарственные пре-параты в эксперименте и клинике / А. С. Дудниченко, Ю. М. Краснопольский, В. И. Швец. — Харьков: РА — Каравелла, 2001. — 144 с.

3.Либман Е. С. Эпидемиологические характеристики инвалидности вследствие основных форм макулопатий / Е. С. Либман, Р. А. Толмачев, Е. В. Шахова // «Макула — 2006» : микролекции, тез. докл., стеногр. дискус. — Ростов-на-Дону : Принт-Терра, 2006. — С. 15-21.

4.Г. С. Полунин и др. Морфофункциональное состояние макулы при ранней стадии возрастной макулярной дегенерации // «Макула — 2006»: микролекции, тез. докл., стеногр. дискус. — Ростов-на-Дону: Принт-Терра, 2006. — С. 365- 366.

5.Age-Related Eye Disease Study Research Group. A ran-domized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss : AREDS report № 8 // Arch Ophthalmol. — 2001. — № 119(10). — P. 1417- 1436.

6.Ambati J. Age-related macular degeneration: ethiology, pathogenesis and therapeutic strategies / J. Ambati, B. Ambati, S. Yoo // Surv. Ophthalmol. — 2003. — Vol.48. — № 3. — Р.257- 291.

7.Algvere P. V. Age-related maculopathy: pathogenetic features and new treatment modalities / P. V. Algvere, S. Seregard // Acta. Ophthalmol. Scand. — 2002. — № 80(2). — P. 136- 143.

8.Bird A. C. An international classification and grading system for age-rel.ated maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. / A. C. Bird, N. M. Bressler, S. B. Bressler et al. // Surv. Ophthalmol. - 1995. - № 39. - V. 5. - p. 367- 374.

9.Chida M. In vitro testing of antioxidants and biochemical end-points in bovine retinal tissue / M. Chida, K. Suzuki, T. Nakanishi-Ueda, et al. // Ophthalmic Res. — 1999. — № 31. - V. 6. - P. 407-415.

10.Hanneken A. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death / A. Hanneken, F. Lin, J. Johnson et al. // Invest. Ophthalmol. Vis Sci. - 2006. - № 47. - V. 7. - P. 3164-3177.

11.Hood D. ISCEV guidelines for clinical multifocal electroretinography (2007 edition) / D. Hood, M. Bach, M. Bridell. et. al. // Doc. Ophthalmol. -   2008. -Vol. 116. - N 1. - P. 1-11

12.Hood D. The Multifocal Electroretinogram / D. Hood, J. Odel, C. Chen et al. // Journal of Neuro-Ophthalmolo-gy. — 2003 — V. 23 — № 3 — P. 225- 235.

13.Kook D. The protective effect of quercetin against oxida¬tive stress in human RPE in vitro /D. Kook, A. Wolf , A. Yu et al. Invest. Ophthalmol. Vis Sci. - 2008. - № 49. -V 4. — P. 1712-1720.

14.Maher P. Flavonoids protect retinal ganglion cells from oxidative-stress-induced death / P. Maher, A. Hanneken // Invest. Ophthalmol. Vis Sci. — 2005. — № 46. — V.12. — P. 4796-4803.